Core 4 - Genome Sequencing Core
Core 4 - Genome Sequencing Core
批准号:
10555738
负责人:
Jens G Lohr
金额:
$31.35万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
未结题
起止时间:
2011-12-01 至 2028-07-31
关键词:
Base PairingBioinformaticsCancer CenterCell CountCellsClinicalCodeDNADNA Sequencing FacilityDNA methylation profilingDNA sequencingDana-Farber Cancer InstituteDataData AnalysesDiagnosisEvolutionFutureGenesGenomic SegmentGenomicsGoalsIndividualInformaticsLaboratoriesMethylationModalityMultiple MyelomaMutationNewly DiagnosedOutputPatientsProcessRelapseResolutionRunningSamplingSampling StudiesScienceSequence AnalysisStandardizationSubgroupTechnologyTestingTimeUntranslated RNAVariantanalysis pipelinecancer genomecancer genomicscell free DNAcost effectiveflexibilitygenome sequencinggenome-wideimprovedinnovationinstrumentnext generation sequencingnovel sequencing technologysequencing platformsingle cell sequencingtargeted sequencingwhole genome
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary – Core 4 – Genome Sequencing Core Dana-Farber Cancer Institute
Whole genome sequencing especially at single cell level is a specialized function requiring expertise, special
instruments and facilities along with informatics capabilities. This function cannot be performed in individual
laboratories. Single cell sequencing is also evolving rapidly and constantly improving the information capabilities,
number of samples per run and data modalities per cell. There is only limited number of facilities available
worldwide with such capabilities to continue to innovate. Dana Farber/Harvard Cancer Center (DF/HCC) is a
major center in the US sequencing significant number of cancer genomes. DFCI is committed to continually
appraising new sequencing technologies, using in-house testing wherever possible, and will use whatever future
technology is most suitable and cost-effective for the applications demanded by the science pursued at the
Institute. The purpose of Core 4 is to provide for comprehensive genomic sequence analyses by utilizing a state
of the art ‘next generation’ sequencing platform for the sequencing of whole genome, targeted regions,
methylated regions, circulating cells as well as single cells and the identification and characterization of genome-
wide somatic alterations in samples detailed in all projects. We have also developed and standardized single
cell and bulk sequencing for various platforms. To meet these goals we will perform whole genome sequencing
and enzymatic methylation sequencing to generate genome wide somatic alterations and methylation changes
with streamlined analysis pipeline from IFM/DFCI 2009 and 2020-02 study samples at diagnosis and when
available at relapse (Specific Aim 1); and generate single-cell whole genome and targeted sequencing data from
selected serial samples to explore clonal changes during MM evolution (Specific Aim 2). Further, the core will
provide bioinformatics expertise in the management and analysis of data produced within the core to support the
projects.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Liquid biopsy in myeloma to inform outcome and treatment decisions
-
批准号:10562684
-
项目类别:
-
资助金额:$40.72万
-
财政年份:2023
-
负责人:Jens G Lohr
-
依托单位:
海外基金